دورية أكاديمية
أعرض في EDS

Toward comprehensive value assessment for Alzheimer's disease innovations.

التفاصيل البيبلوغرافية
العنوان: Toward comprehensive value assessment for Alzheimer's disease innovations.
المؤلفون: Ferrell PB; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana, USA., Fillit H; Alzheimer's Drug Discovery Foundation and Icahn School of Medicine at Mount Sinai, New York, New York, USA., Neumann PJ; Center for the Evaluation of Value and Risk in Health, Tufts Medical Center, Boston, Massachusetts, USA., Wall JK; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana, USA., Murray JF; Davos Alzheimer's Collaborative, Wayne, Pennsylvania, USA.
المصدر: Alzheimer's & dementia : the journal of the Alzheimer's Association [Alzheimers Dement] 2023 Apr; Vol. 19 (4), pp. 1558-1567. Date of Electronic Publication: 2022 Nov 25.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: John Wiley & Sons, Ltd Country of Publication: United States NLM ID: 101231978 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1552-5279 (Electronic) Linking ISSN: 15525260 NLM ISO Abbreviation: Alzheimers Dement Subsets: MEDLINE
أسماء مطبوعة: Publication: 2020- : Hoboken, NJ : John Wiley & Sons, Ltd.
Original Publication: Orlando, FL : Elsevier, Inc.
مواضيع طبية MeSH: Alzheimer Disease*/diagnosis, Humans ; Technology ; Inventions
مستخلص: Introduction: Assessing medical technologies for Alzheimer's disease (AD) creates challenges for current methods of value assessment. New value assessment approaches for AD are also needed.
Methods: We adapted concepts from health economics to help guide decision makers to more informed decisions about AD therapies and diagnostics.
Results: We propose a value framework based on five categories: perspective, value elements, analysis, reporting, and decision making. AD value assessments should include the perspective of the patient-caregiver dyad. We propose a broader array of value elements than currently used. Analytics and decision methods can synthesize evidence for all elements of value. Decisions should use a "deliberative appraisal" approach informed by the composite evidence and be transparently reported.
Discussion: Using the proposed framework, the value of forthcoming innovations for AD may be more thoroughly assessed for and by all stakeholders. It can guide decision makers to carefully consider all relevant elements of value contributing to more holistic and transparent decision making.
Research Highlights: Alzheimer's disease challenges common methods of evaluating medical technology. Using current methods, new AD innovations might not be appropriately valued. Poor value assessments will adversely affect patient access to AD innovations. A full AD value framework expands perspective, elements, analysis, decision-making, reporting.
(© 2022 Eli Lilly and Company and The Authors. Alzheimer's & Dementia published by Wiley Periodicals LLC on behalf of Alzheimer's Association.)
References: 2021 Alzheimer's disease facts and figures. Alzheimers Dement. 2021;17:327-406. doi:10.1002/alz12874.12328.
Wolff JL, Spillman BC, Freedman VA, Kasper JD. A national profile of family and unpaid caregivers who assist older adults with health care activities. JAMA Intern Med. 2016;176:372-379. doi:10.1001/jamainternmed.2015.7664.
Deb A, Thornton JD, Sambamoorthi U, Innes K. Direct and indirect cost of managing alzheimer's disease and related dementias in the United States. Expert Rev Pharmacoecon Outcomes Res. 2017;17:189-202. doi:10.1080/14737167.2017.1313118.
Barbarino P. The essential role of value assessment in addressing the global dementia crisis in Valuing future Alzheimer's disease treatments: the need for a holistic approach. Value Outcomes Spotlight. 2021;7(S1):S5-S6. Accessed May 10, 2022. https://www.ispor.org/publications/journals/value-outcomes-spotlight/vos-archives/issue/view/valuing-future-alz12874heimers-disease-treatments-the-need-for-a-holistic-approach/the-essential-role-of-value-assessment-in-addressing-the-global-dementia-crisis.
Barbarino P, Gustaffson A, Neumann PJ. Long-term value demonstration in Alzheimer's disease: evidence needs in Valuing future Alzheimer's disease treatments: the need for a holistic approach. Value Outcomes Spotlight. 2021;7(S1):S18-S23. Accessed May 10, 2022. https://www.ispor.org/publications/journals/value-outcomes-spotlight/vos-archives/issue/view/valuing-future-alz12874heimers-disease-treatments-the-need-for-a-holistic-approach/long-term-value-demonstration-in-alz12874heimers-disease-evidence-needs.
Kim DD, Silver MC, Kunst N, Cohen JT, Ollendorf DA, Neumann PJ. Perspective and costing in cost-effectiveness analysis, 1974-2018. Pharmacoeconomics. 2020;38:1135-1145. doi:10.1007/s40273-020-00942-2.
Garrison LP, Baumgart M, El-Hayek YH, Holzapfel D, Leibman C. Defining elements of value in Alzheimer's disease in Valuing future Alzheimer's disease treatments: the need for a holistic approach. Value Outcomes Spotlight. 2021;7(S1):S7-S11. Accessed May 10, 2022. https://www.ispor.org/publications/journals/value-outcomes-spotlight/vos-archives/issue/view/valuing-future-alz12874heimers-disease-treatments-the-need-for-a-holistic-approach/defining-elements-of-value-in-alz12874heimers-disease.
Lin PJ, Neumann PJ. Valuing Alzheimer disease therapies-considering costs and benefits beyond the patient. JAMA Netw Open. 2021;4:e2131913. doi:10.1001/jamanetworkopen.2021.31913.
Lin GA, Whittington MD, Synnott PG. Aducanumab for Alzheimer's disease: effectiveness and value; final evidence report and meeting summary. Institute for Clinical and Economic Review, August 5, 2021. Accessed August 26 2021. Available at: https://icer.org/wp-content/uploads/2020/10/ICER_ALZ12874_Final_Report_080521.pdf.
Lakdawalla DN, Doshi JA, Garrison LP, Jr., Phelps CE, Basu A, Danzon PM. Defining elements of value in health care-a health economics approach: an ISPOR special task force report [3]. Value Health. 2018;21:131-139. doi:10.1016/j.jval.2017.12.007.
Sanders GD, Neumann PJ, Basu A, et al. Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: second panel on cost-effectiveness in health and medicine. JAMA. 2016;316:1093-1103. doi:10.1001/jama.2016.12195.
Institute for Clinical and Economic Review. ICER's reference case for economic evaluations: principles and rationale. Jan. 31, 2020. Accessed January 10 2022. https://icer.org/wp-content/uploads/2020/10/ICER_Reference_Case_013120.pdf.
Drummond MF, Neumann PJ, Sullivan SD, et al. Analytic considerations in applying a general economic evaluation reference case to gene therapy. Value Health. 2019;22:661-668. doi:10.1016/j.jval.2019.03.012.
Neumann PJ. Toward better data dashboards for US drug value assessments. Value Health. 2021;24:1484-1489. doi:10.1016/j.jval.2021.04.1287.
Henshall C, Schuller T, Forum HTP. Health technology assessment, value-based decision making, and innovation. Int J Technol Assess Health Care. 2013;29:353-359. doi:10.1017/s0266462313000378.
Porter ME. What is value in health care? N Engl J Med. 2010;363:2477-2481. doi:10.1056/nejmp1011024.
Lu YY, Ellis J, Yang Z, et al. Satisfaction with a family-focused intervention for mild cognitive impairment dyads. J Nurs Scholarsh. 2016;48:334-344. doi:10.1111/jnu.12214.
Fillit HM, Gutterman EM, Brooks RL. Impact of donepezil on caregiving burden for patients with Alzheimer's disease. Int Psychogeriatr. 2000;12:389-401. doi:10.1017/s1041610200006499.
Robinson RL, Rentz DM, Bruemmer V, et al. Observation of patient and caregiver burden associated with early Alzheimer's disease in the United States: design and baseline findings of the GERAS-US cohort study1. J Alzheimers Dis. 2019;72:279-292. doi:10.3233/jad-190430.
National Institute for Health and Care Excellence. Guide to the methods of technology appraisal 2013: Process and methods [PMG9]. April 4, 2013. Accessed March 14 2022. https://www.nice.org.uk/process/pmg9/chapter/the-reference-case?msclkid=4f622041a3cb11ecba8a46e11b57c24c.
Leys M. Health care policy: qualitative evidence and health technology assessment. Health Policy. 2003;65:217-226. doi:10.1016/s0168-8510(02)00209-9.
Cameron WB. Informal Sociology: A Casual Introduction to Sociological Thinking. Random House; 1963.
Murphy E, Dingwall R, Parker S. Qualitative research methods in health technology assessment: a review of the literature. Health Technol Assess. 1998;2(16):1-274.
Facey K, Boivin A, Gracia J. Patients’ perspectives in health technology assessment: a route to robust evidence and fair deliberation. Int J Technol Assess Health Care. 2010;26(3):334-340. doi:10.1017/S0266462310000395.
DiBenedetti DB, Slota C, Wronski SL, et al. Assessing what matters most to patients with or at risk for Alzheimer's and care partners: a qualitative study evaluating symptoms, impacts, and outcomes. Alzheimers Res Ther. 2020;12(1):90. doi:10.1186/s13195-020-00659-6.
Morse JM. Critical analysis of strategies for determining rigor in qualitative inquiry. Qual Health Res. 2015;25(9):1212-1222. doi:10.1177/1049732315588501.
Kitto SC, Janice Chesters J, Grbich C. Quality in qualitative research. Med J Aust. 2008;188(4):243-246. doi:10.5694/j.1326-5377.2008.tb01595.x.
Basu A, Lynn N, Peschin S, Resendez J. Value assessment in Alzheimer's disease: a focus on equity. Value Outcomes Spotlight. 2021;7(S1):S12-S16. Accessed May 10, 2022. https://www.ispor.org/publications/journals/value-outcomes-spotlight/vos-archives/issue/view/valuing-future-alz12874heimers-disease-treatments-the-need-for-a-holistic-approach/value-assessment-in-alz12874heimers-disease-a-focus-on-equity.
Alzheimer Disease International. Dementia facts & figures. Accessed September 23 2021. Available at: https://www.alz12874int.org/about/dementia-facts-figures.
Yuasa A, Yonemoto N, Demiya S, Foellscher C, Ikeda S. Investigation of factors considered by health technology assessment agencies in eight countries. Pharmacoecon Open. 2021;5(1):57-69. doi:10.1007/s41669-020-00235-6.
Ward T, Mujica-Mota RE, Spencer AE, Medina-Lara A. Incorporating equity concerns in cost-effectiveness analyses: a systematic literature review. Pharmacoeconomics. 2022;40(1):45-64. doi:10.1007/s40273-021-01094-7.
Reed C, Barrett A, Lebrec J, et al. How useful is the EQ-5D in assessing the impact of caring for people with Alzheimer's disease? Health Qual Life Outcomes. 2017;15:16. doi:10.1186/s12955-017-0591-2.
Tochel C, Smith M, Baldwin H, et al. What outcomes are important to patients with mild cognitive impairment or Alzheimer's disease, their caregivers, and health-care professionals? A systematic review. Alzheimers Dement (Amst). 2019;11:231-247. doi:10.1016/j.dadm.2018.12.003.
Hauber B, Paulsen R, Callahan L, et al. Quantifying what matters most to patients and care partners in Alzheimer's Disease. Poster presented at the 2020 Alzheimer's Association Virtual International Conference (AAIC), July 29, 2020. Accessed April 7 2022. Available at: https://www.usagainstalz12874heimers.org/sites/default/files/2020-07/40095_Quantifying%20What%20Matters%20Most_0.pdf.
Ito K, Chapman R, Pearson SD, Tafazzoli A, Yaffe K, Gurwitz JH. Evaluation of the cost-effectiveness of drug treatment for Alzheimer disease in a simulation model that includes caregiver and societal factors. JAMA Netw Open. 2021;4:e2129392. doi:10.1001/jamanetworkopen.2021.29392.
McLaughlin T, Feldman H, Fillit H, et al. Dependence as a unifying construct in defining Alzheimer's disease severity. Alzheimers Dement. 2010;6:482-493. doi:10.1016/j.jalz12874.2009.09.004.
Stern Y, Albert SM, Sano M, et al. Assessing patient dependence in Alzheimer's disease. J Gerontol. 1994;49:M216-22. doi:10.1093/geronj/49.5.m216.
Michaud TL, High R, Charlton ME, Murman DL. Dependence stage and pharmacoeconomic outcomes in patients with Alzheimer disease. Alzheimer Dis Assoc Disord. 2017;31:209-217. doi:10.1097/wad.0000000000000198.
Spackman DE, Kadiyala S, Neumann PJ, Veenstra DL, Sullivan SD. The validity of dependence as a health outcome measure in Alzheimer's disease. Am J Alzheimers Dis Other Demen. 2013;28:245-252. doi:10.1177/1533317513481092.
Kahle-Wrobleski K, Andrews JS, Belger M, et al. Dependence levels as interim clinical milestones along the continuum of Alzheimer's disease: 18-month results from the GERAS observational study. J Prev Alzheimers Dis. 2017;4:72-80. doi:10.14283/jpad.2017.2.
Jutkowitz E, Kane RL, Gaugler JE, MacLehose RF, Dowd B, Kuntz KM. Societal and family lifetime cost of dementia: implications for policy. J Am Geriatr Soc. 2017;65:2169-2175. doi:10.1111/jgs.15043.
Lewis F, Schaffer SK, Sussex J, O'Neill P, Cockcroft L. The trajectory of dementia in the UK - making a difference. Report for Alzheimer's Research UK by OHE Consulting. June 9, 2014. Accessed January 19 2022. Available at: https://www.alz12874heimersresearchuk.org/wp-content/uploads/2015/01/OHE-report-Full.pdf?msclkid=c9ff1a3dbc0611ecb3db40178cd60cf4.
Prados MJ, Liu Y, Jun H, Lam J, Mattke S. Projecting the long-term societal value of a disease-modifying treatment for Alzheimer's disease in the United States. Alzheimers Dement. 2022;18:142-151. doi:10.1002/alz12874.12578.
Lakdawalla DN, Phelps CE. Health technology assessment with diminishing returns to health: the Generalized Risk-Adjusted Cost-Effectiveness (GRACE) approach. Value Health. 2021;24:244-249. doi:10.1016/j.jval.2020.10.003.
Defechereux T, Paolucci F, Mirelman A, et al. Health care priority setting in Norway a multicriteria decision analysis. BMC Health Serv Res. 2012;12:39. doi:10.1186/1472-6963-12-39.
Scottish Medicines Consortium. SMC modifiers used in appraising new medicines. 2012. Accessed January 10 2022. Available at: https://www.scottishmedicines.org.uk/media/3565/modifiers.pdf.
Persson U. Value based pricing in Sweden: lessons for design. OHE Seminar Briefing No. 12. London: Office of Health Economics, 2012. Accessed January 10 2022. Available at: https://www.ohe.org/system/files/private/publications/377%20-%20VBP%20in%20Sweden%20Persson%202012.pdf?download=1.
National Institute for Health and Care Excellence. NICE health technology evaluations: the manual. Process and methods [PMG36]: January 31, 2022. Accessed February 21 2022. https://www.nice.org.uk/process/pmg36/resources/nice-health-technology-evaluations-the-manual-pdf-72286779244741.
Philipson TJ, Becker G, Goldman D, Murphy KM. Terminal care and the value of life near its end. NBER Working Paper No. 15649. January 2010. https://ssrn.com/abstract=1537768.
Ten Ham RMT, Frederix GWJ, Wu O. et al. Key considerations in the health technology assessment of advanced therapy medicinal products in Scotland, the Netherlands, and England. Value Health. 2022;25(3):390-399. doi:10.1016/j.jval.2021.09.012.
Garrison LP, Austin MJF. The economics of personalized medicine: a model of incentives for value creation and capture. Drug Inf J. 2007;41:501-509. doi:10.1177/009286150704100408.
Garau M, Towse A, Garrison LP, Housman L, Ossa D. Can and should value-based pricing be applied to molecular diagnostics? London: Research Paper 12/03, Office of Health Economics, April 2012. Accessed January 19 2022. https://papers.ssrn.com/sol3/Delivery.cfm/SSRN_ID2633990_code2358224.pdf?abstractid=2633990&mirid=1.
Zhu H, Mehta M, Huang SM, Wang Y. Toward bridging unmet medical need in early Alzheimer's disease: an evaluation of beta-amyloid (Abeta) plaque burden as a potential drug development tool. Clin Pharmacol Ther. 2022;111:728-731. doi:10.1002/cpt.2536.
EL Ross, Weinberg MS, Arnold SE. Cost-effectiveness of aducanumab and donanemab for early Alzheimer disease in the US. JAMA Neurol. 2022;79(5):478-487. doi:10.1001/jamaneurol.2022.0315.
Tahami Monfared AA, Tafazzoli A, Chavan A, Ye W, Zhang Q. The potential economic value of lecanemab in patients with early Alzheimer's disease using simulation modeling. Neurol Ther. 2022;11(3):1285-1307. doi:10.1007/s40120-022-00373-5.
US Food and Drug Administration. Surrogate endpoint resources for drug and biologic development. July 24, 2018. Accessed April 5, 2022. Available at: https://www.fda.gov/drugs/development-resources/surrogate-endpoint-resources-drug-and-biologic-development.
Elston J, Taylor RS. Use of surrogate outcomes in cost-effectiveness models: a review of United Kingdom health technology assessment reports. Int J Technol Assess Health Care. 2009;25:6-13. doi:10.1017/s0266462309090023.
Busche MA, Hyman BT. Synergy between amyloid-beta and tau in Alzheimer's disease. Nat Neurosci. 2020;23:1183-1193. doi:10.1038/s41593-020-0687-6.
Vreman RA, Mantel-Teeuwisse AK, Hövels AM, Leufkens HGM, Goettsch WG. Differences in health technology assessment recommendations among European jurisdictions: the role of practice variations. Value Health. 2020;23(1):10-16. doi:10.1016/j.jval.2019.07.017.
Goldman D, Lakdawalla D, Philipson TJ, Yin W. Valuing health technologies at NICE: recommendations for improved incorporation of treatment value in HTA. Health Econ. 2010;19(10):1109-1116. doi:10.1002/hec.1654.
US Food and Drug Administration. Benefit-risk assessment in drug regulatory decision-making. March 30, 2018. Accessed June 23, 2022. Available at: https://www.fda.gov/files/about%20fda/published/Benefit-Risk-Assessment-in-Drug-Regulatory-Decision-Making.pdf.
Devlin N, Sussex J. Incorporating multiple criteria in HTA: methods and processes. Office of Health Economics. 2011. Accessed April 4 2022. Available at: https://www.ohe.org/system/files/private/publications/350%20-%20IncorporatingMutlipleCriteria.pdf.
Baltussen R, Marsh K, Thokala P, et al. Multicriteria decision analysis to support health technology assessment agencies: benefits, limitations, and the way forward. Value Health. 2019;22:1283-1288. doi:10.1016/j.jval.2019.06.014.
Oortwijn W, Jansen M, Baltussen R. Use of evidence-informed deliberative processes by health technology assessment agencies around the globe. Int J Health Policy Manag. 2020;9:27-33. doi:10.15171/ijhpm.2019.72.
Bond K, Stiffell R, Ollendorf DA. Principles for deliberative processes in health technology assessment. Int J Technol Assess Health Care. 2020:1-8. doi:10.1017/s0266462320000550.
Olchanski N, Cohen J, Neumann P. Unknown unknowns - uncertainty in health technology assessment: a case study of PARP inhibitors for ovarian cancer. Center for Evaluation of Value and Risk in Health. July 14, 2021. Accessed on Sept. 30, 2022. Available at: https://cevr.tuftsmedicalcenter.org/news/2021/unknown-unknowns.
فهرسة مساهمة: Keywords: Alzheimer's disease; deliberative appraisal; elements of value; evidence dashboards; health technology assessment; multi-criteria decision analysis; patient-caregiver perspective; value analytics; value assessment; value framework; value measures
تواريخ الأحداث: Date Created: 20221125 Date Completed: 20230418 Latest Revision: 20230505
رمز التحديث: 20231215
DOI: 10.1002/alz.12874
PMID: 36427013
قاعدة البيانات: MEDLINE
الوصف
تدمد:1552-5279
DOI:10.1002/alz.12874